Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of MMH-450 in Healthy Volunteers
NCT07708623Phase 1Completed
- Sponsor
- Materia Medica Holding
- Start
- Aug 2025
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 1, open-label trial of MMH-450 in sleep disorders (4 arms), sponsored by Materia Medica Holding. Primary endpoint: Number of adverse events with grade 3 or higher toxicity at 7 days. Started Aug 2025; status: completed.
02
Drugs
MMH-450
03
Conditions
sleep disorders
Beyond the preview
Go deeper on NCT07708623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07708623.